[HTML][HTML] Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices …
SE Oliver - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
SE Oliver
MMWR. Morbidity and mortality weekly report, 2022•cdc.govOn December 16, 2021, after reviewing updated vaccine effectiveness and safety data, the
Advisory Committee on Immunization Practices made a preferential recommendation for the
use of mRNA COVID-19 vaccines over the Janssen adenoviral-vectored COVID-19 vaccine
in all persons aged≥ 18 years in the United States.
Advisory Committee on Immunization Practices made a preferential recommendation for the
use of mRNA COVID-19 vaccines over the Janssen adenoviral-vectored COVID-19 vaccine
in all persons aged≥ 18 years in the United States.
On December 16, 2021, after reviewing updated vaccine effectiveness and safety data, the Advisory Committee on Immunization Practices made a preferential recommendation for the use of mRNA COVID-19 vaccines over the Janssen adenoviral-vectored COVID-19 vaccine in all persons aged≥ 18 years in the United States.
cdc.gov